摘要
目的：探讨拉米夫定联合阿德福韦酯治疗乙肝肝硬化失代偿期临床疗效。方法研究对象选取我院2011年5月～2014年5月收治的乙肝肝硬化失代偿期患者40例，采用随机数字表法分为对照组（20例）和试验组（20例），分别给予阿德福韦酯口服和在此基础上加用拉米夫定口服治疗；比较两组患者治疗前后TBil、ALT及AST等肝功能相关指标水平，乙肝病毒DNA和乙肝e抗原转阴率等。结果试验组患者治疗后TBil、ALT及AST水平均优于对照组、治疗前（P＜0.05）；试验组患者乙肝病毒DNA和乙肝e抗原转阴率均高于对照组（P＜0.05）。结论拉米夫定联合阿德福韦酯治疗乙肝肝硬化失代偿期可有效延缓肝脏功能损伤，促进乙肝病毒转阴。
Objective To investigate clinical effects of lamivudine combined with adefovir dipivoxil in treatment of loss compensation stage of Hepatitis B cirrhosis. Methods 40 patients with loss compensation stage of Hepatitis B cirrhosis were chosen in the period from May 2011 to May 2014 and randomly divided into both group including control group （20 patients） with adefovir dipivoxil used alone and treatment group （20 patients） with lamivudine on the basis of control group, and the related indicators of liver function including TBil, ALT and AST before and after treatment, seroconversion rate of hepatitis B virus DNA and e antigen of hepatitis B of both groups were compared. Results The related indicators of liver function including TBil, ALT and AST after treatment of treatment group was signiifcantly better than control group and before treatment （P〈0.05）. The seroconversion rate of hepatitis B virus DNA and e antigen of hepatitis B of treatment group was signiifcantly better than control group （P〈0.05）. Conclusion Lamivudine combined with adefovir dipivoxil in treatment of loss compensation stage of Hepatitis B cirrhosis can efifciently delayed liver function damage and promote the clearance of hepatitis B virus.
出处
《中国继续医学教育》
2015年第24期144-145,共2页
China Continuing Medical Education
关键词
拉米夫定
阿德福韦酯
乙肝
肝硬化
失代偿
疗效
Lamivudine, Adefovir dipivoxil, Hepatitis B, Cirrhosis, Losscompensation stage, Clinical effects
